MANNKIND CORP (MNKD)
MANNKIND CORP (MNKD) from its SEC filings: 2025 revenue $349.0 million (+22% vs the year before), net margin 2%, free cash flow $13.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $349.0 million |
| Revenue growth | +22% |
| Net income | $5.9 million |
| Net margin | 1.7% |
| Free cash flow | $13.7 million |
| Diluted EPS | $0.02 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +43% |
| Cash | $52.9 million |
| Long-term debt | $76.4 million |
| Share count, 1 year | +5% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.